Krystal Biotech Stock Price, News & Analysis (NASDAQ:KRYS)

$9.56 -0.77 (-7.45 %)
(As of 12/17/2017 02:52 AM ET)
Previous Close$9.56
Today's Range$9.55 - $10.78
52-Week Range$9.01 - $11.98
Volume40,331 shs
Average Volume13,736 shs
Market Capitalization$105.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KRYS
CUSIPN/A
Phone412-586-5830

Debt

Debt-to-Equity RatioN/A
Current Ratio21.30%
Quick Ratio21.30%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares10,240,000

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, November, 13th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.52. View Krystal Biotech's Earnings History.

Where is Krystal Biotech's stock going? Where will Krystal Biotech's stock price be in 2017?

1 brokers have issued 12 month price targets for Krystal Biotech's shares. Their predictions range from $23.00 to $23.00. On average, they expect Krystal Biotech's stock price to reach $23.00 in the next year. View Analyst Ratings for Krystal Biotech.

Who are some of Krystal Biotech's key competitors?

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

When does Krystal Biotech's lock-up period expire?

Krystal Biotech's lock-up period expires on Monday, March 19th. Krystal Biotech had issued 3,960,000 shares in its IPO on September 20th. The total size of the offering was $39,600,000 based on an initial share price of $10.00. After the expiration of Krystal Biotech's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who owns Krystal Biotech stock?

Krystal Biotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Highbridge Capital Management LLC (3.11%). Company insiders that own Krystal Biotech stock include Daniel Janney and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.

Who bought Krystal Biotech stock? Who is buying Krystal Biotech stock?

Krystal Biotech's stock was bought by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC. Company insiders that have bought Krystal Biotech stock in the last two years include Daniel Janney and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech.

How do I buy Krystal Biotech stock?

Shares of Krystal Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Krystal Biotech's stock price today?

One share of Krystal Biotech stock can currently be purchased for approximately $9.56.

How big of a company is Krystal Biotech?

Krystal Biotech has a market capitalization of $105.75 million. Krystal Biotech employs 7 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.


MarketBeat Community Rating for Krystal Biotech (KRYS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Krystal Biotech (NASDAQ:KRYS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$23.00N/AN/A
Price Target Upside: 136.87% upside136.87% upsideN/AN/A

Krystal Biotech (NASDAQ:KRYS) Consensus Price Target History

Price Target History for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$23.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Krystal Biotech (NASDAQ:KRYS) Earnings History and Estimates Chart

Earnings by Quarter for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ KRYS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.74)($1.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Krystal Biotech (NASDAQ:KRYS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.85 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS

Dividends

Dividend History for Krystal Biotech (NASDAQ:KRYS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Krystal Biotech (NASDAQ KRYS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 30.72%
Insider Trades by Quarter for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ KRYS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2017Daniel JanneyDirectorBuy200,000$10.00$2,000,000.00View SEC Filing  
9/22/2017Suma KrishnanCOOBuy100,000$10.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Krystal Biotech (NASDAQ KRYS) News Headlines

Source:
DateHeadline
Krystal Biotech, Inc. (KRYS) Announces Quarterly  Earnings Results, Misses Estimates By $0.52 EPSKrystal Biotech, Inc. (KRYS) Announces Quarterly Earnings Results, Misses Estimates By $0.52 EPS
www.americanbankingnews.com - November 14 at 10:32 AM
BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍
www.reuters.com - November 14 at 1:56 AM
Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial ResultsKrystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 13 at 8:55 PM
Krystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEBKrystal Biotech (KRYS) Announces KB103 Granted Orphan Drug Designation by FDA to Treat Patients With DEB
www.streetinsider.com - November 9 at 7:46 AM
Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis BullosaKrystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
finance.yahoo.com - November 8 at 12:47 PM
Krystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research FoundationKrystal Biotech Receives Equity-Based Award from EB Research Partnership and EB Medical Research Foundation
finance.yahoo.com - November 3 at 1:13 PM
Krystal Biotech Incs Quiet Period To Expire  on October 30th (NASDAQ:KRYS)Krystal Biotech Inc's Quiet Period To Expire on October 30th (NASDAQ:KRYS)
www.americanbankingnews.com - October 23 at 1:22 AM
Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?Is Krystal Biotech Inc (KRYS) Still A Cheap Healthcare Stock?
finance.yahoo.com - October 21 at 5:31 AM
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of SharesKrystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $1,000,000 of Shares
finance.yahoo.com - September 26 at 8:07 AM
Krystal Biotech Inc (KRYS) COO Suma Krishnan Purchases 100,000 SharesKrystal Biotech Inc (KRYS) COO Suma Krishnan Purchases 100,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM
Krystal Biotech Inc (KRYS) Director Daniel Janney Acquires 200,000 SharesKrystal Biotech Inc (KRYS) Director Daniel Janney Acquires 200,000 Shares
www.americanbankingnews.com - September 25 at 7:14 PM
Krystal Biotech Prices IPO at $9.00-$11.00 Per Share (KRYS)Krystal Biotech Prices IPO at $9.00-$11.00 Per Share (KRYS)
www.americanbankingnews.com - September 8 at 1:24 AM

SEC Filings

Krystal Biotech (NASDAQ:KRYS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Krystal Biotech (NASDAQ:KRYS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Krystal Biotech (NASDAQ KRYS) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.